showed a trendp = 0.051
The studies with patients receiving immunotherapy as a second-line treatment or beyond showed a trend towards a significant overall effect (HR = 1.38; p = 0.051) ( Figure S1B ); heterogeneity was high in these studies (Chi 2 = 39.48; p < 0.001; I 2 = 80%). 3.6.